Habermann TM - Search Results

1

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH. Diefenbach CS, et al. Among authors: habermann tm. Br J Haematol. 2015 Nov;171(4):530-8. doi: 10.1111/bjh.13634. Epub 2015 Sep 7. Br J Haematol. 2015. PMID: 26343802 Free PMC article.

2

Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia.

Habermann TM, Andersen JW, Cassileth PA, Bennett JM, Oken MM. Habermann TM, et al. Br J Haematol. 1992 Apr;80(4):466-71. doi: 10.1111/j.1365-2141.1992.tb04559.x. Br J Haematol. 1992. PMID: 1581231 Clinical Trial.

3

S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma.

Witzig TE, Habermann TM, Kurtin PJ, Schroeder G, Stenson MJ, Greipp PR. Witzig TE, et al. Among authors: habermann tm. Cancer. 1995 Sep 15;76(6):1059-64. doi: 10.1002/1097-0142(19950915)76:6<1059::aid-cncr2820760621>3.0.co;2-e. Cancer. 1995. PMID: 8625208

4

Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.

Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Gordon LI, et al. Among authors: habermann tm. J Clin Oncol. 1996 Apr;14(4):1275-81. doi: 10.1200/JCO.1996.14.4.1275. J Clin Oncol. 1996. PMID: 8648384 Clinical Trial.

5

Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Ansell SM, et al. Among authors: habermann tm. J Clin Oncol. 1997 Jun;15(6):2296-301. doi: 10.1200/JCO.1997.15.6.2296. J Clin Oncol. 1997. PMID: 9196143

6

Primary pulmonary lymphoma.

Habermann TM, Ryu JH, Inwards DJ, Kurtin PJ. Habermann TM, et al. Semin Oncol. 1999 Jun;26(3):307-15. Semin Oncol. 1999. PMID: 10375087 Review.

7

A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity.

Gordon LI, Young M, Weller E, Habermann TM, Winter JN, Glick J, Ghosh C, Flynn P, Cassileth PA. Gordon LI, et al. Among authors: habermann tm. Blood. 1999 Nov 15;94(10):3307-14. Blood. 1999. PMID: 10552939 Free article. Clinical Trial.

8

Non-Hodgkin's lymphoma: present status and future prospects.

Habermann TM. Habermann TM. Hosp Pract (1995). 1999 Dec 15;34(13):81-4, 87-8. doi: 10.3810/hp.1999.12.178. Hosp Pract (1995). 1999. PMID: 10611900

9

Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

Horning SJ, Weller E, Kim K, Earle JD, O'Connell MJ, Habermann TM, Glick JH. Horning SJ, et al. Among authors: habermann tm. J Clin Oncol. 2004 Aug 1;22(15):3032-8. doi: 10.1200/JCO.2004.06.088. Epub 2004 Jun 21. J Clin Oncol. 2004. PMID: 15210738 Clinical Trial.

10

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Martin WG, et al. Among authors: habermann tm. J Clin Oncol. 2005 Oct 20;23(30):7614-20. doi: 10.1200/JCO.2005.02.7243. Epub 2005 Sep 26. J Clin Oncol. 2005. PMID: 16186594

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

470 results

Search Page

Filters